title: Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction.
abstract: A 37-year-old man was diagnosed with Wilson disease at the age of 14. His first manifestations were neurological. He was treated with trientine for more than 10 years and suffered from anemia and liver dysfunction. Wilson disease is a genetic disorder characterized by accumulation of copper in the body. Excess copper is toxic, but copper is an essential trace element. Copper-binding ceruloplasmin is important for iron metabolism. Excess copper chelating treatment-induced anemia and iron deposition in the liver was suspected. Proper monitoring of copper status is important for the management of Wilson disease.
authors.affiliation: The Third Department of Internal Medicine, University of Occupational and Environmental Health, Japan School of Medicine, Japan. msrharada@med.uoeh-u.ac.jp
authors.forename: Masaru
authors.initials: M
authors.lastname: Harada
authors.forename: Koichiro
authors.initials: K
authors.lastname: Miyagawa
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Honma
authors.forename: Masaaki
authors.initials: M
authors.lastname: Hiura
authors.forename: Michihiko
authors.initials: M
authors.lastname: Shibata
authors.forename: Toru
authors.initials: T
authors.lastname: Matsuhashi
authors.forename: Shintaro
authors.initials: S
authors.lastname: Abe
authors.forename: Riko
authors.initials: R
authors.lastname: Harada
authors.forename: Akinari
authors.initials: A
authors.lastname: Tabaru
mesh_terms: D000328:Adult; D000740:Anemia / Q000097:blood / Q000139:chemically induced*; D002570:Ceruloplasmin / Q000378:metabolism; D002614:Chelating Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015913:Chelation Therapy / Q000009:adverse effects*; D003300:Copper / Q000378:metabolism; D006432:Hemochromatosis / Q000209:etiology / Q000378:metabolism; D006527:Hepatolenticular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism; D008107:Liver Diseases / Q000209:etiology* / Q000378:metabolism; D008297:Male; D014266:Trientine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D002614:Chelating Agents; D003300:Copper; D007501:Iron; D002570:Ceruloplasmin; D014266:Trientine